Interim Report January–June 2023
ChromoGenics invests in the future with increased marketing initiatives and continued cost focusSecond quarter 2023 · Net sales amounted to SEK 3.8 (2.8) million, an increase of SEK 0.9 million or 32 percent compared to the corresponding quarter in 2022. · Operating expenses improved by 3.7 percent to SEK -17.4 (-18.1) million. · EBITDA amounted to SEK -10.2 (-13.9) million, an improvement of 26 percent. · Cash flow before changes in working capital amounted to SEK -10.5 (-14.7) million, an improvement of SEK 4.2 million compared to Q2 2022. The improvement is driven by the